Economic Evaluation of Transitioning to the 20-Valent Pneumococcal Conjugate Vaccine in the Dutch Paediatric National Immunisation Programme
Sign Up to like & getrecommendations! Published in 2025 at "Infectious Diseases and Therapy"
DOI: 10.1007/s40121-025-01109-2
Abstract: In 2024, the vaccination strategy against pneumococcal disease in the Dutch paediatric population was changed from the 10-valent pneumococcal conjugate vaccine (PCV) (PCV10) to a 15-valent PCV (PCV15) under a 2 + 1 schedule. We aimed to… read more here.
Keywords: disease; pcv20; pcv15; dutch paediatric ... See more keywords
Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants.
Sign Up to like & getrecommendations! Published in 2018 at "Vaccine"
DOI: 10.1016/j.vaccine.2018.02.113
Abstract: BACKGROUND Pediatric use of pneumococcal conjugate vaccines (PCV) has been associated with significant decrease in disease burden. However, disease caused by non-vaccine serotypes has increased. Safety and immunogenicity of 15-valent PCV (PCV15) containing serotypes included… read more here.
Keywords: safety; safety immunogenicity; pcv15; pcv13 ... See more keywords